Explore
Validate
LearnABIN954702
antibody from antibodies-online
Targeting: SEC14L2
C22orf6, KIAA1186, KIAA1658, SPF, TAP, TAP1
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN954702 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-SEC14-Like 2 (S. Cerevisiae) (SEC14L2) (AA 40-69), (N-Term) antibody
- Antibody type
- Polyclonal
- Description
- Protein A column followed by peptide Affinity purification
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Epitope
- N-Term, AA 40-69
- Vial size
- 0.4 mL
- Storage
- Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.
- Handling
- Avoid repeated freezing and thawing.
Submitted references Genetic susceptibility to distinct bladder cancer subphenotypes.
Reduced expression of tocopherol-associated protein (TAP/Sec14L2) in human breast cancer.
PTEN identified as important risk factor of chronic obstructive pulmonary disease.
Guey LT, García-Closas M, Murta-Nascimento C, Lloreta J, Palencia L, Kogevinas M, Rothman N, Vellalta G, Calle ML, Marenne G, Tardón A, Carrato A, García-Closas R, Serra C, Silverman DT, Chanock S, Real FX, Malats N, EPICURO/Spanish Bladder Cancer Study investigators.
European urology 2010 Feb;57(2):283-92
European urology 2010 Feb;57(2):283-92
Reduced expression of tocopherol-associated protein (TAP/Sec14L2) in human breast cancer.
Wang X, Ni J, Hsu CL, Johnykutty S, Tang P, Ho YS, Lee CH, Yeh S
Cancer investigation 2009 Dec;27(10):971-7
Cancer investigation 2009 Dec;27(10):971-7
PTEN identified as important risk factor of chronic obstructive pulmonary disease.
Hosgood HD 3rd, Menashe I, He X, Chanock S, Lan Q
Respiratory medicine 2009 Dec;103(12):1866-70
Respiratory medicine 2009 Dec;103(12):1866-70
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
